EpimAb Biotherapeutics rakes in $120m Series C

EpimAb Biotherapeutics, a clinical stage biotech company, has secured $120 million in Series C financing.

23 March 2021•1 min read
Feature image
LinkedInXEmail
LinkedInXEmail

Related articles